This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1998 May 6;90(9):712.

doi: 10.1093/jnci/90.9.712.

Prognostic importance of low c-erbB2 expression in breast tumors

S Koscielny, P Terrier, M Spielmann, J C Delarue

PMID: 9586670
DOI: 10.1093/jnci/90.9.712

Prognostic importance of low c-erbB2 expression in breast tumors

S Koscielny et al. J Natl Cancer Inst. 1998.

. 1998 May 6;90(9):712.

doi: 10.1093/jnci/90.9.712.

Authors

S Koscielny, P Terrier, M Spielmann, J C Delarue

PMID: 9586670
DOI: 10.1093/jnci/90.9.712

No abstract available

PubMed Disclaimer

Comment in

Re: Prognostic importance of low c-erbB2 expression in breast tumors.
Ferrero-Poüs M, Hacène K, Tubiana-Hulin M, Spyratos F. Ferrero-Poüs M, et al. J Natl Cancer Inst. 1999 Sep 15;91(18):1584-5. doi: 10.1093/jnci/91.18.1584. J Natl Cancer Inst. 1999. PMID: 10491437 No abstract available.

Similar articles

Re: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Spyratos F, Bouchet C, Ferrero-Poüs M, Tubiana-Hulin M, Hacène K. Spyratos F, et al. J Natl Cancer Inst. 2003 Sep 17;95(18):1417-8; author reply 1418. doi: 10.1093/jnci/djg068. J Natl Cancer Inst. 2003. PMID: 13130118 No abstract available.
Re: Prognostic importance of low c-erbB2 expression in breast tumors.
Ferrero-Poüs M, Hacène K, Tubiana-Hulin M, Spyratos F. Ferrero-Poüs M, et al. J Natl Cancer Inst. 1999 Sep 15;91(18):1584-5. doi: 10.1093/jnci/91.18.1584. J Natl Cancer Inst. 1999. PMID: 10491437 No abstract available.
Breast cancer heterogeneity: a mixture of at least two main types?
Anderson WF, Matsuno R. Anderson WF, et al. J Natl Cancer Inst. 2006 Jul 19;98(14):948-51. doi: 10.1093/jnci/djj295. J Natl Cancer Inst. 2006. PMID: 16849671 No abstract available.
Morphological detection of hormone and growth factor receptors in breast cancer.
Kölble K. Kölble K. Recent Results Cancer Res. 2007;176:201-9. doi: 10.1007/978-3-540-46091-6_17. Recent Results Cancer Res. 2007. PMID: 17607927 Review.
Postmenopausal hormone receptor-positive advanced breast cancer.
Connolly RM, Stearns V. Connolly RM, et al. Oncology (Williston Park). 2013 Jun;27(6):571-2, 574, 576 passim. Oncology (Williston Park). 2013. PMID: 23909072 Review. No abstract available.

See all similar articles

Cited by

Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Harigopal M, et al. Am J Pathol. 2010 Apr;176(4):1639-47. doi: 10.2353/ajpath.2010.090711. Epub 2010 Feb 11. Am J Pathol. 2010. PMID: 20150438 Free PMC article. Clinical Trial.
Salivary Protein Profiles among HER2/neu-Receptor-Positive and -Negative Breast Cancer Patients: Support for Using Salivary Protein Profiles for Modeling Breast Cancer Progression.
Streckfus CF, Arreola D, Edwards C, Bigler L. Streckfus CF, et al. J Oncol. 2012;2012:413256. doi: 10.1155/2012/413256. Epub 2012 Apr 10. J Oncol. 2012. PMID: 22570650 Free PMC article.
Aberrations of ERBB2 and TOP2A genes in breast cancer.
Nielsen KV, Müller S, Møller S, Schønau A, Balslev E, Knoop AS, Ejlertsen B. Nielsen KV, et al. Mol Oncol. 2010 Apr;4(2):161-8. doi: 10.1016/j.molonc.2009.11.001. Epub 2009 Nov 18. Mol Oncol. 2010. PMID: 19945923 Free PMC article.
Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.
Ren L, Liu J, Gou K, Xing C. Ren L, et al. J Cancer. 2018 May 24;9(12):2082-2092. doi: 10.7150/jca.23681. eCollection 2018. J Cancer. 2018. PMID: 29937926 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal